Related Experiment Video

Updated: Jul 1, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human

Byung Hak Kim1, Chang-Hong Yin, Qianxu Guo

  • 1Department of Pediatrics, Division of Hematology/Oncology, New York Medical College, Valhalla, NY 10595, USA.

Molecular Cancer Therapeutics
|September 16, 2008
PubMed

Insights

AUH-6-96 is a novel small molecule that inhibits Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling. This compound shows therapeutic potential for cancers with aberrant JAK/STAT pathway activation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Aberrant Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling is frequently observed in human cancers, promoting cancer cell survival and proliferation.
  • Targeting the JAK/STAT pathway with pharmacologic inhibitors presents a promising therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To identify and characterize novel small-molecule inhibitors of JAK/STAT signaling.
  • To evaluate the therapeutic potential of a novel compound, AUH-6-96, in preclinical cancer models.

Main Methods:

  • High-throughput screening using Drosophila cells to identify JAK/STAT signaling inhibitors.
  • In vitro studies using human cancer cell lines (including Hodgkin lymphoma L540) to assess the effects of AUH-6-96 on JAK/STAT pathway components (JAK3, STAT3 phosphorylation, SOCS3 expression).
  • Cell viability assays to determine the selective toxicity of AUH-6-96 towards cancer cells with aberrant JAK/STAT signaling.

Main Results:

  • AUH-6-96 effectively reduced Unpaired-induced transcriptional activity and STAT92E phosphorylation in Drosophila cells.
  • AUH-6-96 inhibited both constitutive and IL-6-induced STAT3 phosphorylation in human cancer cell lines.
  • In L540 cells, AUH-6-96 dose- and time-dependently decreased phosphorylated STAT3 and SOCS3, and reduced JAK3 expression.
  • AUH-6-96 selectively reduced the viability of cancer cells with aberrant JAK/STAT signaling by inducing apoptosis via down-regulation of antiapoptotic genes like Bcl-xL.

Conclusions:

  • AUH-6-96 is a novel small-molecule inhibitor of JAK/STAT signaling.
  • AUH-6-96 demonstrates selective anti-cancer activity by targeting cells with aberrant JAK/STAT signaling.
  • AUH-6-96 holds potential as a therapeutic agent for human cancers driven by JAK/STAT pathway dysregulation.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...